Latest News for: glp

Edit

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple ...

Nasdaq Globe Newswire 24 Mar 2025
(United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist ...
Edit

US Patent Office Grants Closed Loop Medicine Key Patents for Cardiometabolic Capabilities in GLP-1 and ...

Business Wire 24 Mar 2025
Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering ...
Edit

Caution advised when making GLP-1 labeling claims

Food Business News 24 Mar 2025
Claims may come under scrutiny from the Trump administration ....
Edit

Structure Therapeutics CEO on latest GLP-1 developments

CNBC 24 Mar 2025
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill ... .
Edit

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Vietnam News 24 Mar 2025
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist ... The addition of a candidate targeting glucagon, as well as GLP-1 ...
Edit

PODCAST: Lawmakers, Lamont at odds over Medicaid-covered GLP-1s

The CT Mirror 24 Mar 2025
GLP-1’s, drugs like Ozempic and Wegovy, cost Connecticut more than $80 million last year ... WSHU’s Ebong Udoma spoke with CT Mirror’s Katy Golvala to discuss her article, “People call GLP-1s life-changing ... What is a GLP-1?.
Edit

GLP-1 drugs could become tougher to get. 3 cheap supplements that can aid weight loss

Penn Live 23 Mar 2025
Plenty of folks have been using GLP-1s — generic versions of popular weight loss drugs such as Ozempic and Zepbound — to jump-start their health journeys lately. But those folks could be in for bad news ... Fortunately, there are options ... BERBERINE ... FIBER.
Edit

People call GLP-1s life-changing. CT says it can’t afford them.

The CT Mirror 23 Mar 2025
After about a year of limited progress, Makowicki’s physician recommended she start on Mounjaro, a glucagon-like peptide-1 agonist, commonly known as a GLP-1 ... Connecticut’s policy towards Medicaid coverage of GLP-1s has been murky, at best.
Edit

What questions do you have for Brad Olson about GLP-1 drugs and his weight-loss experience?

Wall Street Journal 22 Mar 2025
Join a real-time written chat with WSJ’s Bradley Olson on Monday, March 24, from 3 p.m. to 4 p.m. ET. WSJ subscribers can submit their questions ... .
Edit

An ongoing conversation: Employee benefits and GLP-1 medications in 2025

Business Journal 21 Mar 2025
GLP-1 (glucagon-like peptide) medications, such as Ozempic and Wegovy, have seen a surge in ...
Edit

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy ...

Business Wire 21 Mar 2025
... of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.
Edit

Quantum Health Partners with Vida Health to Launch New GLP-1 Weight Management Solution as Part ...

Business Wire 20 Mar 2025
DUBLIN, Ohio & SAN FRANCISCO--(BUSINESS WIRE)--Quantum Health, the leader in healthcare navigation ...
Edit

DXL CEO says big-and-tall retailer could benefit from GLP-1 drugs

Business Journal 20 Mar 2025
Men's big-and-tall retailer DXL is expecting, perhaps ironically, to benefit from the popularity of GLP-1 drugs such as Ozempic and Zepbound ... .
Edit

A GLP-1 agonist can help reduce weight, sleep apnea and more

Lewiston Sun Journal 19 Mar 2025
DEAR DR. ROACH ... He also has mild, untreated sleep apnea.
Edit

To Your Good Health: A GLP-1 agonist can help reduce weight, sleep apnea and more

The Marshall News Messenger 19 Mar 2025
DEAR DR. ROACH. My 66-year-old husband recently received a diagnosis of heart failure with preserved ejection fraction. He is 5 feet, 7 inches tall, and weighs 270 pounds. He is treating his fluid retention with 100 mg of furosemide daily ....

Article Search

tools
×
×
×
×